Back to top

cell-therapy: Archive

Zacks Equity Research

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

HAENegative Net Change DXCMNegative Net Change PODDNegative Net Change EXASPositive Net Change